去甲基化药物在骨髓增生异常综合征治疗中的进展  

Progress of Hypomethylating Agents in Treatment of Myelodysplastic Syndrome

作　　者：常炳庆[1] 孙婉玲[2] CHANG Bingqing;SUN Wanling(Department of Hematology,Beijing Aerospace General Hospital,Beijing 100075,China;Department of Hematology,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]北京航天总医院血液科,北京100076 [2]首都医科大学宣武医院血液科,北京100053

出　　处：《中国药物警戒》2018年第9期560-563,共4页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(81000200):骨髓增生异常综合征细胞亚群端粒长度与临床特征的关系;北京市卫生系统高层次卫生技术人才培养项目(2011-3-092)

摘　　要：骨髓增生异常综合征(myelodysplastic syndrome,MDS)是起源于造血干细胞的一组异质性髓系克隆性疾病,具有较高的急性髓系白血病转化风险。MDS患者自然病程及预后的异质性很大,必须根据患者的预后分层制定个体化治疗方案。目前去甲基化药物是高危MDS患者治疗的主要手段之一。本文总结归纳了目前具有代表性的去甲基化药物的研究进展,期望对该类药物的临床应用和研究提供参考信息。Myelodysplastic syndrome （MDS） is a group of heterogeneous myeloid clonal diseases originated from hematopoietic stem cells and has a high risk to transform into acute myeloid leukemia. The natural course and prognosis of MDS patients are highly heterogeneous, and individualized treatment plans must be developed according to the stratification of patients＇ prognosis. Currently, hypomethylating agents are one of the main treatments for high-risk MDS patients. This paper summarizes the research progress of representative hypomethylating agents in recent years, and hopes to provide references for the clinical application and research of these drugs.

关 键 词：骨髓增生异常综合征 高危 去甲基化药物 

分 类 号：R965[医药卫生—药理学]